AMENDMENT TO ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • August 11th, 2022 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
This Amendment, dated as of June 7, 2022 (this “Amendment”), to the Royalty Purchase Agreement, dated as of March 30, 2021 (the “Purchase Agreement”), is made and entered into by and among Aptevo Therapeutics Inc., a Delaware corporation (“Seller”) and Healthcare Royalty Partners IV, L.P., a Delaware limited partnership (“Buyer”). Buyer and Seller are each individually referred to herein as a “Party” and, collectively, as the “Parties”. Capitalized terms used but not defined herein (including capitalized terms used in the preamble and recitals hereto) shall have the meanings ascribed to such terms in the Purchase Agreement.
LIMITED Consent AND SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • August 11th, 2022 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • New York
This LIMITED CONSENT AND SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of June 7, 2022, by and among Aptevo Therapeutics inc., a Delaware corporation (“Aptevo Therapeutics”), and APTEVO RESEARCH AND DEVELOPMENT LLC, a Delaware limited liability company (“Aptevo R&D”, and together with Aptevo Therapeutics, each individually, a “Borrower” and collectively, the “Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
NINTH AMENDMENT TO OFFICE LEASEOffice Lease • August 11th, 2022 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
This Ninth Amendment to Office Lease is made and entered into on this 26th day of May 2022 by and between SREH 2018 HOLDINGS LLC as successor in interest to SELIG REAL ESTATE HOLDINGS EIGHT L.L.C., a Washington Limited Liability Company, whose address is 1000 Second Avenue, Suite 1800, Seattle, Washington (hereinafter, the “Lessor”) and APTEVO THERAPEUTICS INC. successor in interest to Emergent Product Development Seattle, LLC whose address is 2401 Fourth Avenue, Suite 1050, Seattle, Washington (hereinafter, the “Lessee”).
